USSTOCK.TODAY
Pre-Market
Log in Sign up

MediWound to Proceed with EscharEx Phase 3 Clinical Trials and Comparison with Madrigal Pharmaceuticals Case

FinanceWire · ·by G4L

MDWD
MDWD MediWound Ltd
$13.82 -2.06%
View chart & analysis →
MDGL MDGL +0.10%
  1. 1MediWound is conducting Phase 3 clinical trials for EscharEx.
  2. 2Madrigal Pharmaceuticals recorded a 268% daily stock price increase on December 19, 2022.
  3. 3MediWound expects to complete enrollment and re-evaluate interim sample size by the end of Q1 2027.

So what's the key point?

MediWound is moving forward with Phase 3 clinical trials for a new drug. Attention is being drawn to this because a similar case previously saw a 268% stock price increase in a single day.

Source FinanceWire · View original ↗

Related 3-line summaries

Madrigal Pharmaceuticals Achieves First Profitable Quarter and Revenue Growth Earnings Whispers · Nov 4Madrigal Pharmaceuticals shares fall ahead of Q3 earnings release Earnings Whispers · Oct 27Paramount weighs selling CNN to clear $110B Warner acquisition GuruFocus.com +4 · Aug 14
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news